{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:51:34Z","timestamp":1783075894535,"version":"3.54.6"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","schres-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.schres.2016.12.016","type":"journal-article","created":{"date-parts":[[2016,12,18]],"date-time":"2016-12-18T02:33:29Z","timestamp":1482028409000},"page":"51-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Effect of smoking on risperidone pharmacokinetics \u2013 A multifactorial approach to better predict the influence on drug metabolism"],"prefix":"10.1016","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3851-4117","authenticated-orcid":false,"given":"Georgios","family":"Schoretsanitis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekkehard","family":"Haen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Stegmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hiemke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Gr\u00fcnder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Paulzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.schres.2016.12.016_bb0005","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1021\/tx0600090","article-title":"Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites","volume":"19","author":"Avent","year":"2006","journal-title":"Chem. Res. Toxicol."},{"issue":"01","key":"10.1016\/j.schres.2016.12.016_bb0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1055\/s-2005-862617","article-title":"Determination of five commonly used antipsychotics in human serum by high performance-liquid chromatography (HPLC) and electrochemical detection","volume":"38","author":"Bader","year":"2005","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1016\/j.schres.2016.12.016_bb0015","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00007691-199902000-00017","article-title":"Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors","volume":"21","author":"Balant-Gorgia","year":"1999","journal-title":"Ther. Drug Monit."},{"issue":"5","key":"10.1016\/j.schres.2016.12.016_bb0020","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.clpt.2003.07.001","article-title":"Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism","volume":"74","author":"Benowitz","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.schres.2016.12.016_bb0025","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/FTD.0b013e3182577c43","article-title":"Risperidone and total 9-hydroxyrisperidone in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2002\u20132010","volume":"34","author":"Bowskill","year":"2012","journal-title":"Ther. Drug Monit."},{"issue":"4","key":"10.1016\/j.schres.2016.12.016_bb0030","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1067\/mcp.2002.127494","article-title":"The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment","volume":"72","author":"Brockmoller","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.schres.2016.12.016_bb0035","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jama.2013.284985","article-title":"Trends in smoking among adults with mental illness and association between mental health treatment and smoking cessation","volume":"311","author":"Cook","year":"2014","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.schres.2016.12.016_bb0040","first-page":"261","article-title":"Effect of tobacco smoking on renal function","volume":"124","author":"Cooper","year":"2006","journal-title":"Indian J. Med. Res."},{"issue":"2","key":"10.1016\/j.schres.2016.12.016_bb0045","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2125.1985.tb02641.x","article-title":"The effects of age and smoking on the plasma protein binding of lignocaine and diazepam","volume":"19","author":"Davis","year":"1985","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.schres.2016.12.016_bb0050","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1176\/ajp.152.3.453","article-title":"Schizophrenia and smoking: an epidemiological survey in a state hospital","volume":"152","author":"de Leon","year":"1995","journal-title":"Am. J. Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.schres.2016.12.016_bb0055","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0920-9964(01)00192-X","article-title":"Schizophrenia and tobacco smoking: a replication study in another US psychiatric hospital","volume":"56","author":"de Leon","year":"2002","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2016.12.016_bb0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4088\/JCP.v66n0103","article-title":"The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation","volume":"66","author":"de Leon","year":"2005","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2016.12.016_bb0065","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/01.mjt.0000146622.59764.dd","article-title":"Clozapine toxicity associated with smoking cessation: case report","volume":"12","author":"Derenne","year":"2005","journal-title":"Am. J. Ther."},{"issue":"2","key":"10.1016\/j.schres.2016.12.016_bb0070","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.clpt.2004.04.003","article-title":"Time response of cytochrome P450 1A2 activity on cessation of heavy smoking","volume":"76","author":"Faber","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.schres.2016.12.016_bb0075","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/PL00005334","article-title":"Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4","volume":"359","author":"Fang","year":"1999","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"issue":"12","key":"10.1016\/j.schres.2016.12.016_bb0080","first-page":"1638","article-title":"In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes","volume":"29","author":"Fang","year":"2001","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.schres.2016.12.016_bb0085","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2125.2008.03276.x","article-title":"Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study","volume":"66","author":"Feng","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.schres.2016.12.016_bb0090","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1017\/S0033291713002705","article-title":"Tobacco smoking in schizophrenia: investigating the role of incentive salience","volume":"44","author":"Freeman","year":"2014","journal-title":"Psychol. Med."},{"issue":"2","key":"10.1016\/j.schres.2016.12.016_bb0095","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S2215-0366(14)00057-1","article-title":"Rethinking the association between smoking and schizophrenia","volume":"2","author":"Gage","year":"2015","journal-title":"Lancet Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2016.12.016_bb0100","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00228-006-0209-9","article-title":"The effect of variable cigarette consumption on the interaction with clozapine and olanzapine","volume":"62","author":"Haslemo","year":"2006","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2016.12.016_bb0105","first-page":"13","article-title":"The pharmacokinetics of risperidone in humans: a summary","volume":"55","author":"Heykants","year":"1994","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2016.12.016_bb0110","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2016.12.016_bb0115","series-title":"Harmonised Tripartite Guideline, Validation of Analytical Procedures: Test and Methodology, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use","author":"ICH Expert Working Group","year":"1996"},{"issue":"1","key":"10.1016\/j.schres.2016.12.016_bb0120","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0278-5846(95)00293-6","article-title":"Haloperidol and reduced haloperidol plasma concentrations after a loading dose regimen with haloperidol decanoate","volume":"20","author":"Jann","year":"1996","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2016.12.016_bb0125","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/JCP.0b013e3181acc372","article-title":"ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine","volume":"29","author":"Jaquenoud Sirot","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2016.12.016_bb0130","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/0091270009343694","article-title":"Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking","volume":"50","author":"Jin","year":"2010","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.schres.2016.12.016_bb0135","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1067\/mcp.2003.21","article-title":"Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking","volume":"73","author":"Kang","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.schres.2016.12.016_bb0140","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(98)00105-4","article-title":"Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials","volume":"35","author":"Leucht","year":"1999","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2016.12.016_bb0145","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2147\/NDT.S106663","article-title":"The prevalence and risk factors of stroke in patients with chronic schizophrenia","volume":"12","author":"Liang","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"5","key":"10.1016\/j.schres.2016.12.016_bb0150","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1055\/s-2007-1014307","article-title":"Seizures following smoking cessation in a clozapine responder","volume":"27","author":"McCarthy","year":"1994","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"10.1016\/j.schres.2016.12.016_bb0155","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/00004714-200112000-00005","article-title":"Individual changes in clozapine levels after smoking cessation: results and a predictive model","volume":"21","author":"Meyer","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.schres.2016.12.016_bb0160","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.1365-2125.2000.00298.x","article-title":"Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine","volume":"50","author":"Olesen","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.schres.2016.12.016_bb0165","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1177\/00912700122010717","article-title":"Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations","volume":"41","author":"Olesen","year":"2001","journal-title":"J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.schres.2016.12.016_bb0170","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1177\/0269881116650390","article-title":"Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions","volume":"30","author":"Paulzen","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2016.12.016_bb0175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.psyneuen.2016.07.009","article-title":"Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; a pharmacokinetics-based hypothesis","volume":"73","author":"Paulzen","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.schres.2016.12.016_bb0180","article-title":"Clinical response in a risperidone-medicated naturalistic sample: patients' characteristics and dose-dependent pharmacokinetic patterns","author":"Paulzen","year":"2016","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"10","key":"10.1016\/j.schres.2016.12.016_bb0185","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/j.1875-9114.2012.01117","article-title":"Effects of tobacco smoking and nicotine on cancer treatment","volume":"32","author":"Petros","year":"2012","journal-title":"Pharmacotherapy"},{"issue":"10","key":"10.1016\/j.schres.2016.12.016_bb0190","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/FPC.0b013e3283498ecf","article-title":"Genetic epidemiology of induced CYP3A4 activity","volume":"21","author":"Rahmioglu","year":"2011","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.schres.2016.12.016_bb0195","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fpsyt.2014.00137","article-title":"Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions","volume":"5","author":"Ringen","year":"2014","journal-title":"Front. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2016.12.016_bb0200","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.jcp.0000106221.36344.4d","article-title":"Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients","volume":"24","author":"Rostami-Hodjegan","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2016.12.016_bb0205","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.eurpsy.2005.07.008","article-title":"Cigarette smoking in long-term schizophrenia","volume":"21","author":"Salokangas","year":"2006","journal-title":"Eur. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2016.12.016_bb0210","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/JCP.0000000000000601","article-title":"Pharmacokinetic drug-drug interactions of mood stabilizers and risperidone in patients under combined treatment","volume":"36","author":"Schoretsanitis","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2016.12.016_bb0215","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/YIC.0000000000000131","article-title":"Risperidone-induced extrapyramidal side effects: is the need for anticholinergics the consequence of high plasma concentrations?","volume":"31","author":"Schoretsanitis","year":"2016","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.schres.2016.12.016_bb0220","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00228-016-2085-2","article-title":"Pharmacokinetic patterns of risperidone-associated adverse drug reactions","volume":"72","author":"Schoretsanitis","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.schres.2016.12.016_bb0225","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-0773.1999.tb02016.x","article-title":"Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients","volume":"85","author":"Seppala","year":"1999","journal-title":"Pharmacol. Toxicol."},{"issue":"2","key":"10.1016\/j.schres.2016.12.016_bb0230","first-page":"67","article-title":"Effect of smoking on pharmacokinetics of antipsychotics","volume":"24","author":"Shimoda","year":"2004","journal-title":"Nihon Shinkei Seishin Yakurigaku Zasshi"},{"issue":"7","key":"10.1016\/j.schres.2016.12.016_bb0235","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1177\/0269881110370504","article-title":"CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics","volume":"25","author":"Suzuki","year":"2011","journal-title":"J. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2016.12.016_bb0240","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/FTD.0000000000000048","article-title":"Effect of smoking on the pharmacokinetics of inhaled loxapine","volume":"36","author":"Takahashi","year":"2014","journal-title":"Ther. Drug Monit."},{"issue":"2","key":"10.1016\/j.schres.2016.12.016_bb0245","first-page":"131","article-title":"Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test","volume":"9","author":"Tantcheva-Poor","year":"1999","journal-title":"Pharmacogenetics"},{"issue":"4","key":"10.1016\/j.schres.2016.12.016_bb0250","first-page":"306","article-title":"Smoking in patients with psychiatric disorders: effects on their psychopathology and quality of life","volume":"19","author":"Tsopelas","year":"2008","journal-title":"Psychiatrike=Psychiatriki"},{"key":"10.1016\/j.schres.2016.12.016_bb0255","author":"US Food and Drug Administration"},{"key":"10.1016\/j.schres.2016.12.016_bb0260","author":"US Food and Drug Administration"},{"issue":"1","key":"10.1016\/j.schres.2016.12.016_bb0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/dmd.110.034504","article-title":"Cigarette smoke extract induces CYP2B6 through constitutive androstane receptor in hepatocytes","volume":"39","author":"Washio","year":"2011","journal-title":"Drug Metab. Dispos."},{"issue":"8","key":"10.1016\/j.schres.2016.12.016_bb0270","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.pnpbp.2008.08.022","article-title":"Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors","volume":"32","author":"Wu","year":"2008","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2016.12.016_bb0275","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1177\/0091270009347867","article-title":"Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety","volume":"50","author":"Xiang","year":"2010","journal-title":"J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.schres.2016.12.016_bb0280","first-page":"1263","article-title":"Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes","volume":"29","author":"Yasui-Furukori","year":"2001","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.schres.2016.12.016_bb0285","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2165\/00003088-199936060-00004","article-title":"Drug interactions with tobacco smoking. An update","volume":"36","author":"Zevin","year":"1999","journal-title":"Clin. Pharmacokinet."},{"issue":"12","key":"10.1016\/j.schres.2016.12.016_bb0290","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1124\/dmd.108.023671","article-title":"Interindividual variation in relative CYP1A2\/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes","volume":"36","author":"Zhang","year":"2008","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.schres.2016.12.016_bb0295","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1745-7254.2006.00256.x","article-title":"Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia","volume":"27","author":"Zhou","year":"2006","journal-title":"Acta Pharmacol. Sin."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996416305904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996416305904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T07:52:32Z","timestamp":1718956352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996416305904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":59,"alternative-id":["S0920996416305904"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2016.12.016","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of smoking on risperidone pharmacokinetics \u2013 A multifactorial approach to better predict the influence on drug metabolism","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2016.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}